Summary Serum levels of TAG 72 were measured in 726 serum samples from patients with benign and malignant gynaecological conditions in order to evaluate the clinical usefulness of TAG 72 alone or in combination with other tumour markers. Sixty-six per cent of patients with ovarian cancer showed abnormal concentrations of TAG 72 antigen. A good correlation was also found between serial TAG 72 values and the clinical course of disease during chemotherapy and follow-up. In cervical and endometrial cancer abnormal TAG 72 values occurred in 23% and 14% of cases, while none of the patients with breast cancer had abnormal TAG 72 levels. Among patients with benign disease only one out of 12 patients (8%) with benign ovarian tumours and one of 15 patients with uterine fibromyomatosis (7%) showed high TAG 72 serum levels. However, the determination of TAG 72 did not increase the sensitivity of CA 125 and squamous cell carcinoma antigen (SCC), in ovarian and cervical cancer, respectively. The systemic administration of recombinant interferon alpha-2b to 15 patients with ovarian cancer and different basal levels of TAG 72 did not increase serum levels of the antigen.
The clinical management of gynaecological malignancies has, like other areas of oncology, increasingly benefited from the development of monoclonal antibodies to tumour associated antigens. Two markers are of particular interest, namely the OC-125 antigen associated with ovarian tumours and the squamous cell carcinoma antigen (SCC) of cervical cancer (Bast et al., 1983; Kato et al., 1977) . Although serum levels of both macromolecules are currently employed to monitor the clinical course of these two malignancies, both markers suffer from a number of limitations.
Determination of CA 125 is often associated with false negative results in early stages of the disease and in patients with low tumour burden (Bast et al., 1983; Niloff et al., 1985; Berek et al., 1986; Schilthuis et al., 1986; Benedetti Panici et al., 1987) . Only 50% of squamous cervical cancers are associated with the expression of the SCC antigen (Kato et al., 1977 (Kato et al., , 1984 Mauro et al., 1985; Senekjian et al., 1987) .
More recently, the pancarcinoma associated antigen TAG 72 identified by MoAb B72.3 (Colcher et al., 1981) has received increasing attention because of its expression in almost all ovarian epithelial tumours (Johnson et al., 1985; ). An additional interesting feature of TAG-72 is its upregulation by interferons (IFNs), at least in experiments in vitro (Greiner et al., 1984; Guadagni et al., 1987) and in vivo models . Although preliminary findings (Klug et al., 1986) have shown that elevated serum levels of TAG 72 are present in a high percentage of ovarian cancer patients, no extensive data are yet available as to whether the measurement of this marker in patients with gynaecological tumours offers advantages in terms of specificity and sensitivity over available assays.
In the present study we addressed these issues by comparatively measuring TAG 72, CA 125 and SCC in a large group of patients affected by gynaecological malignancies. Moreover, in order to verify whether IFN treatment can also facilitate the detection of TAG 72 in the circulation, we serially evaluated its levels during a short treatment with recombinant Table I shows the median level, range and percentage of positivity of TAG 72 in patients with benign and malignant gynaecological tumours. Although CA 72.4 RIA assay seems to be more sensitive than B 72.3 MKS IRMA, no statistically significant difference between the two assays was found in any of the gynaecological malignancies examined. Moreover, linear regression analysis revealed a statistically significant correlation (P<0.01) between values obtained with the two assays (data not shown). Therefore, in continuing the study we only referred to data obtained with the CA 72.4 RIA assay.
Abnormally high TAG 72 values were seen most frequently in ovarian tumours. Elevated levels of TAG 72 occurred in 29 out of 44 patients (66%) with primary epithelial ovarian cancer. Among patients with uterine tumours, abnormal TAG 72 levels were only found in 15 (23%) and six (14%) cervical and endometrial cancer patients, respectively. None of the 20 patients with breast cancer had elevated CA 72.4 levels. All patients with endometriosis and endometrial hyperplasia showed TAG 72 levels within the normal range. Only one of 12 (8%) patients with benign ovarian tumours and one out of 15 (7%) with uterine fibromyomatosis had slightly increased TAG 72 levels. In patients with advanced ovarian cancer who underwent cytoreductive surgery, a good correlation was found between TAG 72 levels and residual tumours after surgery (Table IV) . Five out of 12 (42%) patients, with residual disease >0.5 cm showed abnormal TAG 72 serum levels with respect to one out of four patients (25%) without residual disease. However, CA 125 was more sensitive than TAG 72 in detecting residual disease after surgery.
TAG 72 and clinical course of disease In 18 patients TAG 72 levels were measured during chemotherapy, consisting of three courses of high dose cisplatin (200 mg m2) (Benedetti Panici et al., 1987) . Figure 1 shows serum TAG 72 levels before and at completion of chemo- Recombinant alpha-2b interferon was administered (5 x 106 U daily, i.m.) for 3 consecutive days (days 1-111) and TAG 72 was measured daily for 3 days after the first injection. Based on these findings it can be suggested that TAG 72 assay could be of some value in the differential diagnosis of pelvic tumours in order to reduce the false positive results of CA 125. Moreover, the high specificity of MAB B 72.3 for malignant tissues suggests that this antibody could be useful for tumour radioimmunodetection and possibly immunotherapy. It is also worth noting that Colcher et al. (1984) reported a prolonged binding of radiolabelled B 72.3 when used for the in situ radioimmunodetection of human colon carcinoma xenografts. Recently, preliminary data from Surwit et al. (1989) indicated that labelled B 72.3 could be successfully used for immunoscanning of patients with ovarian cancer. Compared to ovarian cancer in uterine tumours, the sensitivity of TAG 72 assay was very low: 14% in endometrial cancer and 23% in cervical cancer. In these neoplasias only patients with advanced disease were found to have significantly positive TAG 72 serum levels. Moreover, in cervical cancer quantification of TAG 72 does not improve the sensitivity of SCC alone.
As previously reported by Klug et al. (1986) , elevated levels of TAG 72 are only rarely present in the sera of patients with breast cancer. This is rather surprising since MAB B 72.3 was generated using a membrane-enriched extract of a breast tumour metastasis as immunogen and has high level of reactivity with at least 50% of all breast carcinomas (Colcher et al., 1981) . Although the discrepancy between the tissue and serological expression might reflect the heterogeneity of antigen expression in malignant cells within a tumour (Stramignoni et al., 1983) , it can also be hypothesised that TAG 72 might be shed into circulation by different tumours at different rates. These findings also suggest that the serum TAG 72 assay cannot be used for screening candidates for tumour radioimmunodetection with radiolabelled B 72.3.
Because the sensitivity of radioimmunometric methods employing MoAb may be significantly influenced by the type of combination of reagent employed, we analysed our panel of sera using two different commercially available TAG 72 detection kits.
Our results did not show any significant advantage of TAG 72 measurement with a double antibody assay with respect to a single antibody assay, suggesting that at least in gynaecological malignancies this antigen contains multiple epitopes for B 72.3. Much interest has been focused on the finding that the surface expression of TAG 72 is increased by IFNs both in vitro on human breast and colon cancer cells (Grenier et al., 1984; Guadagni et al., 1987) and in vivo in human tumour xenograft in nude mice (Grenier et al., 1986) . However, the systemic administration of rIFN alpha-2b to 15 patients with ovarian cancer and different basal values of TAG 72 did not stimulate TAG 72 levels. Our negative findings can be explained as follows: (1) a more prolonged exposure to rIFN alpha-2b and/or a longer lead time after IFN administration could be necessary in order to observe an increase of TAG 72 levels; (2) different types of IFNs could be more effective than rIFN alpha-2b in the stimulation of TAG 72 expression; (3) IFNs could stimulate the surface expression of TAG 72 without a concomitant release of the antigen in the circulation. The first two possibilities seem rather unlikely. Several species of rIFN alpha, including rIFN alpha B, are able to stimulate the surface binding of MAB B 72.3 at very low concentrations with a lead time between rIFN treatment and TAG 72 increase of 24-36h . It is also worth noting that using the same experimental procedure as that employed in this study we detected a marked increase of the circulating levels of a 90,000 Da antigen with a close temporal correlation between in vitro and in vivo data (Iacobelli et al., 1988; Scambia et al., 1990) . Our data agree with the recent findings of Boyer et al. (1989) , who were unable to demonstrate any IFN-induced increase of TAG 72 expression in six ovarian cancer cell lines in vitro.
In conclusion, our findings suggest that the serum assay of TAG 72 has only a limited value in the clinical management of patients with gynaecological malignancies. Further studies should be carried out to verify the possible role of B 72.3 in the pre-operative differential diagnosis of pelvic masses as well as in tumour radioimmunodetection.
